News Image

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Provided By PR Newswire

Last update: Jan 6, 2025

CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.

Read more at prnewswire.com

CITIUS ONCOLOGY INC

NASDAQ:CTOR (3/7/2025, 8:16:37 PM)

After market: 0.966 +0.03 (+2.77%)

0.94

-0.08 (-7.84%)


CITIUS PHARMACEUTICALS INC

NASDAQ:CTXR (3/7/2025, 8:16:41 PM)

After market: 1.8 +0.01 (+0.56%)

1.79

+0.01 (+0.56%)



Find more stocks in the Stock Screener

Follow ChartMill for more